The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical and biologic factors associated with time to progression in patients treated by first-line palliative FOLFOX chemotherapy in metastatic colorectal cancer.
Wieslaw Bal
No relevant relationships to disclose
Michal Jarzab
No relevant relationships to disclose
Ewa Stobiecka
No relevant relationships to disclose
Jadwiga Zebracka
No relevant relationships to disclose
Marta Mianowska
No relevant relationships to disclose
Malgorzata Oczko-Wojciechowska
No relevant relationships to disclose
Dagmara Rusinek
No relevant relationships to disclose
Tomasz Tyszkiewicz
No relevant relationships to disclose
Elzbieta Nowara
No relevant relationships to disclose
Barbara Jarzab
No relevant relationships to disclose
Rafal Tarnawski
No relevant relationships to disclose